Chemotherapy and targeted agents for elderly women with advanced breast cancer

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Breast cancer is the most common malignancy in women worldwide, and represents the leading cause of death in the female population. Incidence of breast cancer increases with age, and older patients are more likely to have disseminated disease at diagnosis. For those patients who relapse after endocrine treatment or in which the tumor does not express hormone receptors, chemotherapy should be considered. Single agent sequential regimens should be preferred to combination regimens, which are usually more toxic and provide a limited survival gain. New drugs which have proven efficacy against metastatic breast cancer are Taxanes (Paclitaxel and Docetaxel), Vinorelbine, Capecitabine, Gemcitabine, various and newer formulations of Anthracyclines (Epirubicin, oral Idarubicin, liposomal Doxorubicin). The anti-HER2 monoclonal antibody Trastuzumab in association with chemotherapy can be administered to elderly patients who present with HER2 overexpressing tumors, though cardiac monitoring is necessary due to cardiac adverse events. Bevacizumab, an anti-VEGF monoclonal antibody, was recently patented and approved in combination with Paclitaxel for the treatment of metastatic breast cancer. Globally, there is need to develop therapeutics able to circumvent resistance against hormonal and other therapies for advanced breast cancer, which are expected to be safe and effective in this age class.

Original languageEnglish
Pages (from-to)187-201
Number of pages15
JournalRecent Patents on Anti-Cancer Drug Discovery
Volume3
Issue number3
DOIs
Publication statusPublished - 2008

Fingerprint

Breast Neoplasms
Drug Therapy
docetaxel
gemcitabine
Paclitaxel
Monoclonal Antibodies
Idarubicin
Taxoids
Epirubicin
Heart Neoplasms
Poisons
Anthracyclines
Therapeutics
Vascular Endothelial Growth Factor A
Cause of Death
Neoplasms
Hormones
Recurrence
Survival
Incidence

Keywords

  • Bevacizumab
  • Breast cancer
  • Capecitabine
  • Chemotherapy
  • Docetaxel
  • Elderly
  • Gemcitabine
  • Idarubicin
  • Paclitaxel
  • Pegylated liposomal doxorubicin
  • Protein-bound paclitaxel
  • Trastuzumab
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology (medical)
  • Drug Discovery

Cite this

@article{60046cf7d5b646c38c7aede54157a0cd,
title = "Chemotherapy and targeted agents for elderly women with advanced breast cancer",
abstract = "Breast cancer is the most common malignancy in women worldwide, and represents the leading cause of death in the female population. Incidence of breast cancer increases with age, and older patients are more likely to have disseminated disease at diagnosis. For those patients who relapse after endocrine treatment or in which the tumor does not express hormone receptors, chemotherapy should be considered. Single agent sequential regimens should be preferred to combination regimens, which are usually more toxic and provide a limited survival gain. New drugs which have proven efficacy against metastatic breast cancer are Taxanes (Paclitaxel and Docetaxel), Vinorelbine, Capecitabine, Gemcitabine, various and newer formulations of Anthracyclines (Epirubicin, oral Idarubicin, liposomal Doxorubicin). The anti-HER2 monoclonal antibody Trastuzumab in association with chemotherapy can be administered to elderly patients who present with HER2 overexpressing tumors, though cardiac monitoring is necessary due to cardiac adverse events. Bevacizumab, an anti-VEGF monoclonal antibody, was recently patented and approved in combination with Paclitaxel for the treatment of metastatic breast cancer. Globally, there is need to develop therapeutics able to circumvent resistance against hormonal and other therapies for advanced breast cancer, which are expected to be safe and effective in this age class.",
keywords = "Bevacizumab, Breast cancer, Capecitabine, Chemotherapy, Docetaxel, Elderly, Gemcitabine, Idarubicin, Paclitaxel, Pegylated liposomal doxorubicin, Protein-bound paclitaxel, Trastuzumab, Vinorelbine",
author = "Antonella Brunello and Anna Roma and Cristina Falci and Umberto Basso",
year = "2008",
doi = "10.2174/157489208786242313",
language = "English",
volume = "3",
pages = "187--201",
journal = "Recent Patents on Anti-Cancer Drug Discovery",
issn = "1574-8928",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Chemotherapy and targeted agents for elderly women with advanced breast cancer

AU - Brunello, Antonella

AU - Roma, Anna

AU - Falci, Cristina

AU - Basso, Umberto

PY - 2008

Y1 - 2008

N2 - Breast cancer is the most common malignancy in women worldwide, and represents the leading cause of death in the female population. Incidence of breast cancer increases with age, and older patients are more likely to have disseminated disease at diagnosis. For those patients who relapse after endocrine treatment or in which the tumor does not express hormone receptors, chemotherapy should be considered. Single agent sequential regimens should be preferred to combination regimens, which are usually more toxic and provide a limited survival gain. New drugs which have proven efficacy against metastatic breast cancer are Taxanes (Paclitaxel and Docetaxel), Vinorelbine, Capecitabine, Gemcitabine, various and newer formulations of Anthracyclines (Epirubicin, oral Idarubicin, liposomal Doxorubicin). The anti-HER2 monoclonal antibody Trastuzumab in association with chemotherapy can be administered to elderly patients who present with HER2 overexpressing tumors, though cardiac monitoring is necessary due to cardiac adverse events. Bevacizumab, an anti-VEGF monoclonal antibody, was recently patented and approved in combination with Paclitaxel for the treatment of metastatic breast cancer. Globally, there is need to develop therapeutics able to circumvent resistance against hormonal and other therapies for advanced breast cancer, which are expected to be safe and effective in this age class.

AB - Breast cancer is the most common malignancy in women worldwide, and represents the leading cause of death in the female population. Incidence of breast cancer increases with age, and older patients are more likely to have disseminated disease at diagnosis. For those patients who relapse after endocrine treatment or in which the tumor does not express hormone receptors, chemotherapy should be considered. Single agent sequential regimens should be preferred to combination regimens, which are usually more toxic and provide a limited survival gain. New drugs which have proven efficacy against metastatic breast cancer are Taxanes (Paclitaxel and Docetaxel), Vinorelbine, Capecitabine, Gemcitabine, various and newer formulations of Anthracyclines (Epirubicin, oral Idarubicin, liposomal Doxorubicin). The anti-HER2 monoclonal antibody Trastuzumab in association with chemotherapy can be administered to elderly patients who present with HER2 overexpressing tumors, though cardiac monitoring is necessary due to cardiac adverse events. Bevacizumab, an anti-VEGF monoclonal antibody, was recently patented and approved in combination with Paclitaxel for the treatment of metastatic breast cancer. Globally, there is need to develop therapeutics able to circumvent resistance against hormonal and other therapies for advanced breast cancer, which are expected to be safe and effective in this age class.

KW - Bevacizumab

KW - Breast cancer

KW - Capecitabine

KW - Chemotherapy

KW - Docetaxel

KW - Elderly

KW - Gemcitabine

KW - Idarubicin

KW - Paclitaxel

KW - Pegylated liposomal doxorubicin

KW - Protein-bound paclitaxel

KW - Trastuzumab

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=58049198447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58049198447&partnerID=8YFLogxK

U2 - 10.2174/157489208786242313

DO - 10.2174/157489208786242313

M3 - Article

C2 - 18991787

AN - SCOPUS:58049198447

VL - 3

SP - 187

EP - 201

JO - Recent Patents on Anti-Cancer Drug Discovery

JF - Recent Patents on Anti-Cancer Drug Discovery

SN - 1574-8928

IS - 3

ER -